Literature DB >> 22474617

Parkinson's disease: gene therapies.

Philippe G Coune1, Bernard L Schneider, Patrick Aebischer.   

Abstract

With the recent development of effective gene delivery systems, gene therapy for the central nervous system is finding novel applications. Here, we review existing viral vectors and discuss gene therapy strategies that have been proposed for Parkinson's disease. To date, most of the clinical trials were based on viral vectors to deliver therapeutic transgenes to neurons within the basal ganglia. Initial trials used genes to relieve the major motor symptoms caused by nigrostriatal degeneration. Although these new genetic approaches still need to prove more effective than existing symptomatic treatments, there is a need for disease-modifying strategies. The investigation of the genetic factors implicated in Parkinson's disease is providing precious insights in disease pathology that, combined with innovative gene delivery systems, will hopefully offer novel opportunities for gene therapy interventions to slow down, or even halt disease progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22474617      PMCID: PMC3312404          DOI: 10.1101/cshperspect.a009431

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  100 in total

1.  Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.

Authors:  Frank Soldner; Josée Laganière; Albert W Cheng; Dirk Hockemeyer; Qing Gao; Raaji Alagappan; Vikram Khurana; Lawrence I Golbe; Richard H Myers; Susan Lindquist; Lei Zhang; Dmitry Guschin; Lauren K Fong; B Joseph Vu; Xiangdong Meng; Fyodor D Urnov; Edward J Rebar; Philip D Gregory; H Steve Zhang; Rudolf Jaenisch
Journal:  Cell       Date:  2011-07-14       Impact factor: 41.582

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  In vivo enhancement of tyrosine hydroxylation in rat striatum by tetrahydrobiopterin.

Authors:  R Kettler; G Bartholini; A Pletscher
Journal:  Nature       Date:  1974-05-31       Impact factor: 49.962

4.  GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

Authors:  Mickael Decressac; Ayse Ulusoy; Bengt Mattsson; Biljana Georgievska; Marina Romero-Ramos; Deniz Kirik; Anders Björklund
Journal:  Brain       Date:  2011-06-28       Impact factor: 13.501

5.  Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats.

Authors:  Jean-Charles Paterna; Joram Feldon; Hansruedi Büeler
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons.

Authors:  Haruhiko Kishima; Thomas Poyot; Jocelyne Bloch; Julien Dauguet; Françoise Condé; Frédéric Dollé; Françoise Hinnen; William Pralong; Stéphane Palfi; Nicole Déglon; Patrick Aebischer; Philippe Hantraye
Journal:  Neurobiol Dis       Date:  2004-07       Impact factor: 5.996

8.  Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia.

Authors:  H Ichinose; T Ohye; K Fujita; F Pantucek; K Lange; P Riederer; T Nagatsu
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1994

9.  Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.

Authors:  C Lo Bianco; N Déglon; W Pralong; P Aebischer
Journal:  Neurobiol Dis       Date:  2004-11       Impact factor: 5.996

10.  Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain.

Authors:  K D Beck; J Valverde; T Alexi; K Poulsen; B Moffat; R A Vandlen; A Rosenthal; F Hefti
Journal:  Nature       Date:  1995-01-26       Impact factor: 49.962

View more
  31 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

Review 2.  Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives.

Authors:  Khosro Jamebozorgi; Eskandar Taghizadeh; Daryoush Rostami; Hosein Pormasoumi; George E Barreto; Seyed Mohammad Gheibi Hayat; Amirhossein Sahebkar
Journal:  Mol Neurobiol       Date:  2018-11-05       Impact factor: 5.590

Review 3.  Gene-based therapies in Parkinson's disease.

Authors:  Patricia J Allen; Andrew Feigin
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

4.  There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.

Authors:  P R Lowenstein; Viveka Nand Yadav; Peter Chockley; Maria Castro
Journal:  Mol Ther       Date:  2014-02       Impact factor: 11.454

5.  Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors:  Kristiana Xhima; Fadl Nabbouh; Kullervo Hynynen; Isabelle Aubert; Anurag Tandon
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

Review 6.  Design of virus-based nanomaterials for medicine, biotechnology, and energy.

Authors:  Amy M Wen; Nicole F Steinmetz
Journal:  Chem Soc Rev       Date:  2016-07-25       Impact factor: 54.564

7.  Interaction between nonviral reprogrammed fibroblast stem cells and trophic factors for brain repair.

Authors:  G Liu; H Anisman; J Bobyn; S Hayley
Journal:  Mol Neurobiol       Date:  2014-03-28       Impact factor: 5.590

8.  Roles of Rheb(S16H) in substantia nigra pars compacta dopaminergic neurons in vivo.

Authors:  Min-Tae Jeon; Sang Ryong Kim
Journal:  Biomed Rep       Date:  2014-12-09

Review 9.  Gene Therapy Strategies to Restore ER Proteostasis in Disease.

Authors:  Vicente Valenzuela; Kasey L Jackson; Sergio P Sardi; Claudio Hetz
Journal:  Mol Ther       Date:  2018-04-07       Impact factor: 11.454

10.  Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.

Authors:  Wei Han; Shraddha Sapkota; Richard Camicioli; Roger A Dixon; Liang Li
Journal:  Mov Disord       Date:  2017-09-07       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.